CASI CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Inc is engaged in research and development of biopharmaceutical products. It mainly focuses on acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs.

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/30/2001
Outstanding shares:  139,797,487
Average volume:  1,724,719
Market cap:   $132,010,767
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    14757U109
ISIN:        US14757U1097
Valuation   (See tab for details)
PE ratio:   -2.76
PB ratio:   1.44
PS ratio:   5.11
Return on equity:   -52.25%
Net income %:   -175.18%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy